OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
17
Results
Show all
Save search
Copy query
Show results for
Unknown
(17)
Publication Date
Release Date
2021
(5)
2024
(3)
2023
(2)
2025
(1)
2022
(1)
2019
(1)
2018
(1)
2015
(1)
2010
(1)
2008
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Not available
S-EPMC10794000
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594
|
biostudies-literature
Cite
Tracking Parkinson's: Study Design and Baseline Patient Data.
Not available
S-EPMC4927877
|
biostudies-literature
Cite
Global disparities in surgeons' workloads, academic engagement and rest periods: the on-calL shIft fOr geNEral SurgeonS (LIONESS) study.
Not available
S-EPMC11455666
|
biostudies-literature
Cite
Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors.
Not available
S-EPMC10962646
|
biostudies-literature
Cite
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.
Not available
S-EPMC2748264
|
biostudies-literature
Cite
Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction.
Not available
S-EPMC2911350
|
biostudies-literature
Cite
A second update on mapping the human genetic architecture of COVID-19.
Not available
S-EPMC10482689
|
biostudies-literature
Cite
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets